Vitruvias Therapeutics Thyroid Tablet Recall: What to Know
Written and medically reviewed by Dr. Baraa Alnahhal, MD · Last reviewed: September 30, 2026
The Vitruvias Therapeutics thyroid tablet recall covers one lot of Thyroid Tablets, USP 30 mg, a prescription medicine for an underactive thyroid. Testing showed the tablets may be superpotent, meaning they may contain more thyroid hormone than the label says. The recalled lot is 504950 (NDC 69680-166-00, expiring 9/30/2026). On September 22, 2026, the FDA raised it to a Class I recall, its most serious level (FDA recall notice).
If you take thyroid tablets, do not stop them on your own. Ask your pharmacist to check your lot number and talk to your doctor about a replacement.
Key takeaways
What: Thyroid Tablets, USP 30 mg, lot 504950, NDC 69680-166-00, expiration date 9/30/2026.
Why: Possible superpotency (too much thyroid hormone per tablet).
Who: Vitruvias Therapeutics, Inc. of Auburn, Alabama (often searched as "Vitruvia Therapeutics").
How big: 3,655 units released and 1,955 units sold, distributed nationwide in the U.S.
Risk level: Class I, the FDA's most serious recall category.
Reported harm: No adverse events had been reported when the recall was announced.
What to do: Keep taking your medicine until you speak to a professional, check your lot, and watch for signs of too much thyroid hormone.
Which thyroid tablets are being recalled?
The recall covers a single lot. Here are the details from the company's announcement, posted by the FDA on August 24, 2026, and the later Class I classification.
Detail | Information |
|---|---|
Company | Vitruvias Therapeutics, Inc. (Auburn, Alabama) |
Product | Thyroid Tablets, USP 30 mg |
NDC | 69680-166-00 |
Lot (batch) number | 504950 |
Expiration date | 9/30/2026 |
Units | 3,655 released; 1,955 sold |
Distributed | Nationwide (U.S.), January 31, 2025 to September 30, 2025 |
Reason | Potential superpotency found in testing |
Recall announced | August 21, 2026 (posted by FDA August 24, 2026) |
FDA classification | Class I, September 22, 2026 |
Company contact | (256) 239-9373 or safety@vitruvias.com, Monday to Friday, 9 a.m. to 5 p.m. CT |
Only lot 504950 is part of this recall. Other lots, other strengths, and thyroid medicines made by other companies are not included.
What is Thyroid Tablets, USP?
Thyroid Tablets, USP is a desiccated (dried) thyroid medicine made from animal thyroid glands. It is in the same family as products such as Armour Thyroid and is often called natural desiccated thyroid, or NDT. Unlike levothyroxine, which contains only T4, it contains both main thyroid hormones: T4 and T3 (MedlinePlus).
Doctors prescribe it to replace hormone the body is not making, mainly in hypothyroidism (underactive thyroid). The dose is adjusted carefully using blood tests, so even small changes in how much hormone a tablet delivers can matter.
What does "superpotent" mean?
A superpotent tablet contains more active ingredient than its label states. For this lot, that means a 30 mg tablet may deliver more thyroid hormone than intended.
Taking more thyroid hormone than your body needs can push you into a medicine-caused overactive thyroid state. It looks and feels like hyperthyroidism: the body's systems speed up, and the heart takes much of the strain.
Why is this a Class I recall?
The FDA sorts recalls into three classes by level of risk (FDA):
Class I: a reasonable probability of serious health problems or death.
Class II: may cause temporary or medically reversible health problems.
Class III: not likely to cause health problems.
The company first announced a voluntary recall in August 2026. The FDA later reviewed the risk and classified it as Class I, because excess thyroid hormone can cause heart rhythm problems, especially in people who are more vulnerable.
Symptoms of too much thyroid medicine
According to the recall notice, too much thyroid hormone can cause:
Fast heartbeat, palpitations or an irregular heart rhythm
Chest pain
High blood pressure
Nervousness or feeling on edge
Unplanned weight loss
Feeling too hot (heat intolerance) or sweating more
Tiredness and muscle weakness
Higher-risk groups: the company warns that older adults, pregnant women and infants are more likely to have problems. In my clinical experience, people with existing heart disease also need extra caution, because a faster heart rate adds strain on the heart.
When to get emergency help
Call 911 or go to the emergency room if you take thyroid medicine and have chest pain, a very fast or irregular heartbeat, fainting, severe shortness of breath, or sudden confusion. If you think someone took too much, you can also call Poison Control at 1-800-222-1222.
How to check if your thyroid tablets are affected
Read the drug name and strength. The recall is only for Thyroid Tablets, USP 30 mg.
Find the NDC and lot number. Look for NDC 69680-166-00 and lot 504950, with expiration 9/30/2026.
Call your pharmacist if you cannot find them. Pharmacies often pour tablets into their own bottles, so your label may not show the maker's lot. Your pharmacist can look it up.
Check the maker. If your tablets are not from Vitruvias Therapeutics, they are not part of this recall.
What to do if you have the recalled lot
Do not stop suddenly. The company and FDA advise talking to your healthcare provider before stopping. Missing thyroid medicine can bring back hypothyroid symptoms.
Call your pharmacy. Ask for a replacement from an unaffected lot or another product your doctor approves.
Talk to your doctor. Mention any symptoms. Your doctor may order a thyroid blood test (TSH and free T4) to check your levels. This questions to ask your doctor checklist can help you prepare.
Contact the company with questions. Vitruvias Therapeutics: (256) 239-9373 or safety@vitruvias.com, Monday to Friday, 9 a.m. to 5 p.m. CT.
Report side effects. You or your doctor can report problems to the FDA's MedWatch program online, by mail, or by fax (1-800-FDA-0178).
Note that this lot's expiration date is September 30, 2026. Tablets should not be used after their expiration date in any case, so ask your pharmacist about safe disposal.
Other thyroid medicine recalls in 2026
This is not the only thyroid medicine recall this year. Earlier in summer 2026, separate recalls affected levothyroxine sodium from Major Pharmaceuticals (July, Class II) and from Intas Pharmaceuticals for Accord Healthcare (August). Those recalls involve a different medicine and are not connected to the Vitruvias recall (The Epoch Times).
Frequently asked questions
Why were Vitruvias Therapeutics thyroid tablets recalled?
Testing showed one lot of Thyroid Tablets, USP 30 mg may be superpotent, meaning the tablets may contain more thyroid hormone than the label says. Too much thyroid hormone can cause symptoms of an overactive thyroid.
Which lot of thyroid tablets is recalled?
Only lot 504950 (NDC 69680-166-00, expiration 9/30/2026). It was distributed nationwide in the U.S. from January 31, 2025 to September 30, 2025.
Is the Vitruvias thyroid tablet recall Class I?
Yes. The FDA classified it as Class I on September 22, 2026. Class I is the most serious level, used when there is a reasonable probability of serious health problems or death.
Should I stop taking my thyroid medicine?
No. Do not stop on your own. Call your pharmacist to check your lot, and your doctor to arrange a replacement and, if needed, a thyroid blood test.
What are the symptoms of taking too much thyroid medicine?
A fast or irregular heartbeat, chest pain, nervousness, weight loss, feeling too hot, sweating, tiredness, muscle weakness and high blood pressure. Older adults, pregnant women and infants are at higher risk.
Is Vitruvia Therapeutics the same as Vitruvias Therapeutics?
Yes. Many people search for "Vitruvia Therapeutics," but the company that issued this recall is Vitruvias Therapeutics, Inc., based in Auburn, Alabama.
Sources
This article is for general education and does not replace advice from your own doctor or pharmacist. Always talk to a healthcare professional before changing or stopping any medicine.
Comments